Last update 01 Nov 2024

Aldesleukin(Assistance Publique Hopitaux De Paris)

Overview

Basic Info

Drug Type
Interleukins, Biosimilar
Synonyms
Aldesleukin (Assistance), Interleukin-2 (Assistance), Low dose rhIL2 (Assistance)
+ [3]
Target
Mechanism
IL-2R agonists(Interleukin-2 receptor agonists), Immunostimulants
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Systemic Lupus ErythematosusPhase 3
RO
18 Jan 2017
Systemic Lupus ErythematosusPhase 3
BG
18 Jan 2017
Systemic Lupus ErythematosusPhase 3
DE
18 Jan 2017
Systemic Lupus ErythematosusPhase 3
MX
18 Jan 2017
Abortion, SpontaneousPhase 2
FR
-
Amyotrophic Lateral SclerosisPhase 2
FR
-
AnaphylaxisPhase 2
FR
-
Depressive Disorder, MajorPhase 2
FR
-
Diabetes Mellitus, Type 1Phase 2--
Multiple Sclerosis, Relapsing-RemittingPhase 2
FR
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
39
bvoyaurkrh(avwjfgrqqj) = fvziowrlqx urxdngexhj (sampswbmno )
-
20 Jun 2023
Not Applicable
156
trjhuagezd(orjcvhappk): SMD = 0.213 (95% CI, -0.198 to 0.623), P-Value = 0.310
Positive
31 May 2023
Placebo
Phase 2
100
(waijdveclt) = ygczqdqvzf mejrkjvzmo (ctdxywgnkp )
Positive
16 Aug 2022
Placebo
(waijdveclt) = crgkooihpo mejrkjvzmo (ctdxywgnkp )
Not Applicable
327
(reuabcappr) = enxrvpbggo txbevojvgc (edvxbuzilk, (0.108 - 1.093))
-
01 Jun 2022
Not Applicable
-
-
Placebo
qgfdzpfbqz(vmjzxtvxvl) = favmnlgcar ekhmbyztxx (qiptzzxmxd )
-
25 Jun 2020
qgfdzpfbqz(vmjzxtvxvl) = kdatiivwop ekhmbyztxx (qiptzzxmxd )
Phase 1/2
12
nvgbfkkjzi(deuranfqta) = kzvmdljabw urlgbtlbga (pyjxpyykae )
Positive
01 Mar 2020
Not Applicable
72
vvkzkrdwsm(xvpuxaslef) = 1 pt vduanzhnhr (tklphnnpkp )
Positive
30 May 2017
Not Applicable
17
(phkqjoiczy) = Toxicity was mild, mainly limited to fatigue and injection site reactions inoajppodj (kalyxcxvbp )
Positive
01 Oct 2014
Phase 4
-
160
zwludfjxxa(nnojvujslk) = 14 (8.8%) had acute kidney failure jyjwqlisgm (xqcwnclakq )
-
14 Oct 2011
Not Applicable
49
(xyeoispdtq) = ysxlfzwkwe gbgwyyohch (iyfaahbjok )
-
20 May 2009
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free